SCHEMBL4131647

SCHEMBL4131647

COC(=O)c1cc(Br)cn1C(=O)OC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.42
HDAC1 Q13547 2/20 0.36
KDR P35968 1/20 0.36
USP30 Q70CQ3 3/20 0.35
UCHL1 P09936 1/20 0.35
NOTUM Q6P988 1/20 0.35
BCHE P06276 1/20 0.34
EED O75530 1/20 0.33
RBBP4 Q09028 1/20 0.33
SUZ12 Q15022 1/20 0.33
EZH2 Q15910 1/20 0.33
AEBP2 Q6ZN18 1/20 0.33
HTR6 P50406 1/20 0.33
HDAC6 Q9UBN7 1/20 0.32
LMNA P02545 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
BUB1 O43683 1/20 0.32
NPC1 O15118 1/20 0.32
RECQL P46063 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14953037 0.84 BCHE (0.36) HDAC1USP30BCHEHTR6LMNA
SCHEMBL14164204 0.84 NR1H2 (0.44) NR1H2HDAC1KDRBCHEEED
SCHEMBL3436434 0.84 L3MBTL1 (0.43) LMNAL3MBTL1RAB9ASMN1; SMN2
SCHEMBL7715247 0.82 NR1H2 (0.42) NR1H2HDAC1KDRBCHEEED
SCHEMBL21587951 0.81 BCHE (0.33) HDAC1USP30BCHEHTR6LMNA
SCHEMBL15284215 0.79 NR1H2 (0.40) NR1H2HDAC1KDRBCHEEED
SCHEMBL19008980 0.79 NR1H2 (0.40) NR1H2HDAC1KDRBCHEEED
SCHEMBL20141700 0.79 KDM4E (0.36) NOTUML3MBTL1KDM4E
SCHEMBL21366814 0.78 NR1H2 (0.40) NR1H2HDAC1KDRBCHEEED
SCHEMBL21643765 0.78 NR1H2 (0.40) NR1H2HDAC1KDRUSP30UCHL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12466813-B2 PRC1 inhibitors and methods of treatment therewith THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2025-11-11 US disclosed
EP-4155293-B1 PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH UNIV MICHIGAN REGENTS (US) 2025-07-30 EP disclosed
CN-119421872-A Heterocyclic derivative inhibitor, preparation method and application thereof 上海翰森生物医药科技有限公司 2025-02-11 CN disclosed
US-12215116-B2 Arginase inhibitors and methods of use MERCK SHARP & DOHME LLC (US) 2025-02-04 US disclosed
CN-112533581-B PRC1 inhibitors and methods of treatment therewith 密歇根大学董事会 2024-08-30 CN disclosed
CN-118221655-A Heterocyclic derivative inhibitor, preparation method and application thereof 上海翰森生物医药科技有限公司 2024-06-21 CN disclosed
CN-110475776-B Tricyclic carboxamides for combating arthropods 拜耳作物科学股份公司 2024-03-19 CN disclosed
EP-3813784-B1 PRC1 INHIBITORS AND PRC1 INHIBITORS FOR USE IN METHODS OF TREATMENT THEREWITH UNIV MICHIGAN REGENTS (US) 2024-01-10 EP disclosed
US-11825838-B2 Tricyclic carboxamides for controlling arthropods BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2023-11-28 US disclosed
WO-2023107597-A2 BICYCLIC HETEROAROMATIC AMIDE COMPOUNDS AND USES THEREOF Kineta, Inc. (US) 2023-06-15 WO disclosed
US-20170190713-A1 FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF WUXI APPTEC (HONG KONG) CO., LIMITED (HK) 2017-07-06 US disclosed
US-9469608-B2 Thrombin inhibitors MERCK SHARP & DOHME CORP. (US) 2016-10-18 US disclosed
US-9469608-B2 Thrombin inhibitors MERCK SHARP & DOHME CORP. (US) 2016-10-18 US disclosed
US-20150315141-A1 Thrombin Inhibitors MERCK SHARP & DOHME CORP. (US) 2015-11-05 US disclosed
US-20150315141-A1 Thrombin Inhibitors MERCK SHARP & DOHME CORP. (US) 2015-11-05 US disclosed
WO-2014154723-A1 NOVEL PYRROLE DERIVATIVES FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2014-10-02 WO disclosed
WO-2014154723-A1 NOVEL PYRROLE DERIVATIVES FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2014-10-02 WO disclosed
US-20090093476-A1 PYRROLO[1,2-A]QUINOXALINE DERIVATIVES AS ADENOSINE A3 RECEPTOR MODULATORS AND USES THEREOF FAUST PHARMACEUTICALS (FR) 2009-04-09 US disclosed
US-20090093476-A1 PYRROLO[1,2-A]QUINOXALINE DERIVATIVES AS ADENOSINE A3 RECEPTOR MODULATORS AND USES THEREOF FAUST PHARMACEUTICALS (FR) 2009-04-09 US disclosed
US-20090093476-A1 PYRROLO[1,2-A]QUINOXALINE DERIVATIVES AS ADENOSINE A3 RECEPTOR MODULATORS AND USES THEREOF FAUST PHARMACEUTICALS (FR) 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11825838-B2 Tricyclic carboxamides for controlling arthropods AADAC, FAAH, FAAH2 NR1H2 4242/4885HDAC1 272/4885KDR 4209/4885
US-20150315141-A1 Thrombin Inhibitors F3, F2, F9 NR1H2 715/4885HDAC1 949/4885KDR 447/4885
US-12466813-B2 PRC1 inhibitors and methods of treatment therewith BMI1, EZH2, CBX3 NR1H2 1972/4885HDAC1 21/4885KDR 3488/4885
US-20090093476-A1 PYRROLO[1,2-A]QUINOXALINE DERIVATIVES AS ADENOSINE A3 RECEPTOR MODULATORS AND USES THEREOF ADORA3, ADORA2A, ADORA1 NR1H2 1658/4885HDAC1 4307/4885KDR 1137/4885
US-12215116-B2 Arginase inhibitors and methods of use ARG1, ARG2, PRMT1 NR1H2 159/4885HDAC1 152/4885KDR 2372/4885
US-20170190713-A1 FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF MKNK2, CYP2J2, PTGS2 NR1H2 703/4885HDAC1 452/4885KDR 2292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.